Compare Cassava Sciences Inc (FLNA) vs Palo Alto Networks Inc (PANW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Palo Alto Networks Inc — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while Palo Alto Networks Inc trades at $355.45 (market cap $288.53B). The key difference: Palo Alto Networks Inc is far larger — about 5429.6× Cassava Sciences Inc's market cap, and Palo Alto Networks Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | PANW | |
|---|---|---|
Market Cap | $53.14M | $288.53B |
Sector | Health | Technology |
52-Week High | $4.64 | $357.53 |
52-Week Low | $1.09 | $141.67 |
Enterprise Value | -$33.43M | $287.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.
The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.
Palo Alto Networks (PANW) stock surged 6.84% to $352.89, reflecting strong market momentum amid a sector-wide cybersecurity rally. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $0.85 surpassing the $0.793 estimate. Technical indicators show a bullish trend, while analyst sentiment remains overwhelmingly positive with 74% buy ratings. The company's revenue growth trajectory is solid, projected to reach $10.6B in 2026, though valuation ratios remain elevated with a P/E of 307.84 and P/S of 24.58.
The outlook for PANW is favorable due to accelerating AI-driven cybersecurity demand and strong execution, but risks include premium valuation compression and intensifying competition from Fortinet and Zscaler. While free cash flow generation remains healthy at $3.72B in 2025, the stock trades above the consensus price target of $339.56, suggesting near-term consolidation may precede further gains as the company capitalizes on platformization and AI security tailwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Palo Alto Networks Inc
Palo Alto Networks is a pure-play cybersecurity vendor that sells security appliances, subscriptions, and support into enterprises, government entities, and service providers. The company's product portfolio includes firewall appliances, virtual firewalls, endpoint protection, cloud security, and cybersecurity analytics. The Santa Clara, California, firm was established in 2005 and sells its products worldwide.
Read more on PANW →
